JERUSALEM, Dec 17 (Reuters) - (This Dec.17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they ...

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing. CVS' Aetna sues drug manufacturers ...

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International ...

Teva also boasts a compelling growth trajectory, with revenue expected to increase by 15% and EBIT by 30% from 2024 to 2028. Free cash flow yield, currently at 9.8%, is projected to exceed 16% by ...